Is there a future for selective estrogen-receptor modulators in osteoporosis?

Therapeutic Advances in Musculoskeletal Disease

Volumn 4, Issue 2, 2012, Pages 55-59

  Güerri Fernández, Roberto C ^a   Diez Perez, Adolfo ^b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL DEL MAR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ARZOXIFENE; BAZEDOXIFENE; LASOFOXIFENE; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ARTHRALGIA; BONE DENSITY; BREAST CANCER; CANCER PREVENTION; CEREBROVASCULAR ACCIDENT; DEEP VEIN THROMBOSIS; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG MARKETING; DRUG SAFETY; EDITORIAL; FLU LIKE SYNDROME; FRACTURE REDUCTION; FRAGILITY FRACTURE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; LEG CRAMP; LUNG EMBOLISM; MENOPAUSE; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; RISK REDUCTION; SIDE EFFECT; SPINE FRACTURE; SWEATING; SWELLING; UNSPECIFIED SIDE EFFECT;

EID: 84868637507     PISSN: 1759720X     EISSN: 17597218     Source Type: Journal    
DOI: 10.1177/1759720X11435677     Document Type: Editorial

References (29)

1. Barrett-Connor E. Mosca L. Collins P. Geiger M.J. Grady D. Kornitzer M. et al. (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355: 125–137.
2. Bentler S.E. Liu L. Obrizan M. Cook E.A. Wright K.B. Geweke J.F. et al. (2009) The aftermath of hip fracture: discharge placement, functional status change, and mortality. Am J Epidemiol 170: 1290–1299.
3. Black D.M. Arden N.K. Palermo L. Pearson J. Cummings S.R. (1999) Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group. J Bone Miner Res 14: 821–828.
4. Black D.M. Cummings S.R. Karpf D.B. Cauley J.A. Thompson D.E. Nevitt M.C. et al. (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348: 1535–1541.
5. Byrjalsen I. Leeming D.J. Qvist P. Christiansen C. Karsdal M.A. (2008) Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies. Osteoporos Int 19: 339–348.
6. Cosman F. Lindsay R. (1999) Selective estrogen receptor modulators: clinical spectrum. Endocr Rev 20: 418–434.
7. Cummings S.R. Eckert S. Krueger K.A. Grady D. Powles T.J. Cauley J.A. et al. (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281: 2189–2197.
8. Cummings S.R. Ensrud K. Delmas P.D. LaCroix A.Z. Vukicevic S. Reid D.M. et al. (2010) Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 362: 686–696.
9. Cummings S.R. McClung M. Reginster J.Y. Cox D. Mitlak B. Stock J. et al. (2011) Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women. J Bone Miner Res 26: 397–404.
10. Delmas P.D. Bjarnason N.H. Mitlak B.H. Ravoux A.C. Shah A.S. Huster W.J. et al. (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337: 1641–1647.
11. Early Breast Cancer Trialists’ Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687–1717.
12. Ettinger B. Black D.M. Mitlak B.H. Knickerbocker R.K. Nickelsen T. Genant H.K. et al. (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282: 637–645.
13. Fisher B. Costantino J.P. Redmond C.K. Fisher E.R. Wickerham D.L. Cronin W.M. (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86: 527–537.
14. Greendale G.A. DeAmicis T.A. Bucur A. Bretsky P. Rowe J.W. Reuben D.B. et al. (2000) A prospective study of the effect of fracture on measured physical performance: results from the MacArthur Study – MAC. J Am Geriatr Soc 48: 546–549.
15. Harris S.T. Watts N.B. Genant H.K. McKeever C.D. Hangartner T. Keller M. et al. (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282: 1344–1352.
16. Johnston C.C. Jr. Bjarnason N.H. Cohen F.J. Shah A. Lindsay R. Mitlak B.H. et al. (2000) Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med 160: 3444–3450.
17. Kannus P. Parkkari J. Sievanen H. Heinonen A. Vuori I. Jarvinen M. (1996) Epidemiology of hip fractures. Bone 18 (1 Suppl): 57S–63S.
18. Lindsay R. Gallagher J.C. Kagan R. Pickar J.H. Constantine G. (2009) Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril 92: 1045–1052.
19. Lobo R.A. Pinkerton J.V. Gass M.L. Dorin M.H. Ronkin S. Pickar J.H. et al. (2009) Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril 92: 1025–1038.
20. Love R.R. Mazess R.B. Barden H.S. Epstein S. Newcomb P.A. Jordan V.C. et al. (1992) Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326: 852–856.
21. Manson J.E. Hsia J. Johnson K.C. Rossouw J.E. Assaf A.R. Lasser N.L. et al. (2003) Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349: 523–534.
22. McClung M.R. Geusens P. Miller P.D. Zippel H. Bensen W.G. Roux C. et al. (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344: 333–340.
23. Powles T.J. Hickish T. Kanis J.A. Tidy A. Ashley S. (1996) Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14: 78–84.
24. Raisz L.G. (2005) Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 115: 3318–3325.
25. Riggs B.L. Hartmann L.C. (2003) Selective estrogen-receptor modulators – mechanisms of action and application to clinical practice. N Engl J Med 348: 618–629.
26. Rossouw J.E. Anderson G.L. Prentice R.L. LaCroix A.Z. Kooperberg C. Stefanick M.L. et al. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288: 321–333.
27. Silverman S.L. Christiansen C. Genant H.K. Vukicevic S. Zanchetta J.R. de Villiers T.J. et al. (2008) Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 23: 1923–1934.
28. Wassertheil-Smoller S. Hendrix S.L. Limacher M. Heiss G. Kooperberg C. Baird A. et al. (2003) Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 289: 2673–2684.
29. Wolinsky F.D. Fitzgerald J.F. Stump T.E. (1997) The effect of hip fracture on mortality, hospitalization, and functional status: a prospective study. Am J Public Health 87: 398–403.